Propanc Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PPCB research report →
Price Chart
About the company
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development.
- CEO
- James Nathanielsz
- IPO
- 2012
- Employees
- 2
- HQ
- Camberwell, VIC, AU
Get TickerSpark's AI analysis on PPCB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.51M
- P/E
- -0.03
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.10
- EV/EBITDA
- -0.21
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -148.23%
- ROIC
- -161.15%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-57,278,131
- Net Income
- $-58,923,300-3135.8%
- EPS
- $-371.25+99.0%
- OCF Growth
- +56.7%
- FCF Growth
- +56.7%
- 52W High
- $113.97
- 52W Low
- $0.95
- 50D MA
- $1.46
- 200D MA
- $6.88
- Beta
- 3.27
- RSI (14)
- 40
- Avg Volume
- 3.87M
No earnings-call transcripts are available for PPCB yet.
- Free Float
- 54.9%
- Shares Outstanding
- 2.28M
- Float Shares
- 1.25M
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 5, 23 | ZELINGER JOSEF | other | 15,000,000 |
| Aug 17, 21 | Kenyon Julian Norman | other | 3,420,000 |
| Aug 17, 21 | Nathanielsz James Andrew | other | 5,928,000 |
| Aug 17, 21 | Nathanielsz James Andrew | other | 2,800,000 |
| Aug 17, 21 | ZELINGER JOSEF | other | 0 |
| Jun 24, 19 | Campiciano Carlo M | other | 0 |
| May 14, 19 | Kenyon Julian Norman | other | 9,750,000 |
| May 14, 19 | Kenyon Julian Norman | other | 9,750,000 |
| May 14, 19 | Nathanielsz James Andrew | other | 19,500,000 |
| May 14, 19 | Nathanielsz James Andrew | other | 19,500,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PPCB coverage
Recent articles, reports, and earnings notes.
No research on PPCB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PPCB report →Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
globenewswire.com · Aug 18
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
globenewswire.com · Aug 12
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
globenewswire.com · Aug 6
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
globenewswire.com · Aug 5
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
globenewswire.com · Jul 21
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
globenewswire.com · Jul 7
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
globenewswire.com · Jul 2
Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
globenewswire.com · Jun 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.